Donaldson Company, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and first nine months ended April 30, 2023; comparisons are to the same periods in 2022 unless stated otherwise. Amounts are in millions, except per-share data.
Business context and reporting period
Donaldson is a global filtration products and solutions company reporting under three segments: Mobile Solutions, Industrial Solutions and Life Sciences. The company adopted this segment structure effective November 1, 2022 and recast prior-period segment information.
Financial performance and position
| Metric | Three months ended April 30 | Nine months ended April 30 |
|---|---|---|
| Net sales | $875.7; up 2.6% | $2,551.3; up 5.6% |
| Gross margin | 33.0%, versus 31.5% | 33.7%, versus 32.1% |
| Operating income | $124.0, versus $111.0 | $359.6, versus $314.2 |
| Net earnings | $93.7, up 13.0% | $266.9, up 15.2% |
| Diluted EPS | $0.76, versus $0.67 | $2.16, versus $1.85 |
For the first nine months, operating cash flow was $353.7, compared with $143.9. Capital expenditures were $92.8; acquisitions used $62.3; dividends paid were $84.1; and share repurchases were $119.3. Cash declined $7.3 to $186.0 from July 31, 2022.
At April 30, 2023, total debt was approximately $622.1, comprising short-term borrowings and current and long-term debt; total debt was 32.4% of capitalization, versus 36.4% at July 31, 2022. The company reported $655.6 of borrowing capacity across its facilities, including $422.5 available on its $500.0 revolving facility. It was in compliance with debt covenants. Management said available cash, operating cash generation and credit facilities should meet requirements for the next 12 months and beyond.
Current assets were $1,352.6 and current liabilities were $712.0. Inventories were $449.7, down from $502.4 at July 31, 2022. The filing reports no clear consolidated operating margin separate from the income statement; operating income was 14.2% of sales for the quarter and 14.1% for the nine-month period.
Material changes and segment trends
- Industrial Solutions: Third-quarter sales rose 13.8% to $261.5 and pretax segment earnings increased to $49.1 from $34.3. Nine-month sales rose 13.6% to $737.6 and pretax earnings increased to $133.0 from $86.1. Pricing, volume, operational efficiencies and expense leverage contributed; foreign exchange reduced sales.
- Mobile Solutions: Third-quarter sales were essentially flat at $555.0; pretax earnings rose to $83.4 from $79.7. Nine-month sales increased 4.9% to $1,632.3 and pretax earnings rose to $242.3 from $203.9. Quarterly aftermarket sales declined as large OEM customers normalized inventories.
- Life Sciences: Third-quarter sales fell 12.6% to $59.2 and pretax earnings fell to $0.2 from $14.0. Nine-month sales declined 14.1% to $181.4 and pretax earnings fell to $17.3 from $51.1. Management attributed weakness chiefly to lower disk-drive demand and expected initial negative earnings from acquisitions.
- Foreign currency translation reduced sales by $23.6 in the quarter and $116.6 for the nine months; management estimated the nine-month translation impact also reduced net earnings by $14.5.
Outlook, commentary, risks and unusual items
- No specific numerical earnings or revenue guidance is provided. Management cited pricing and volume growth as sales drivers, while noting foreign-exchange headwinds and continuing inflation in raw materials, labor and energy. Pricing actions generally mitigated, but did not eliminate, margin pressure from higher input costs.
- Organizational redesign and related actions generated charges in fiscal 2023, including severance and redesign costs and expenses mainly related to exiting a lower-margin customer program. The filing describes $7.6 of first-quarter charges and $9.3 of second-quarter charges.
- Donaldson acquired Isolere Bio for $62.3 net of cash acquired in the third quarter. Its sales were immaterial in the reported periods; purchase accounting remains preliminary. The acquisition added $28.1 of goodwill and $44.5 of intangible assets.
- A $3.3 pension settlement charge was recorded in the third quarter. Litigation liabilities were reported as not material, and management said it was remote that currently identified claims would settle materially above recorded accruals.
- Key disclosed risks include global economic and geopolitical conditions, customer demand and inventory changes, inflation and commodity costs, foreign exchange, interest rates, supply and labor constraints, competition, cybersecurity, and acquisition execution. A 0.5 percentage-point increase in short-term rates was estimated to increase nine-month interest expense by approximately $0.7.
Investor verification points
- Assess whether Life Sciences demand and profitability recover, and whether recent acquisitions become accretive as anticipated.
- Track aftermarket customer inventory normalization and demand across Mobile Solutions end markets.
- Compare pricing benefits with continuing input-cost inflation and foreign-exchange effects on sales and earnings.
- Review the sustainability of operating cash flow, which improved substantially alongside inventory reductions, and planned capital spending and shareholder returns.
- Monitor debt maturities, variable-rate exposure, revolving-credit availability and compliance with covenants.
- Follow final purchase accounting for Isolere and potential contingent consideration payments, including the Purilogics-related obligations.